All News
Filter News
Found 808,967 articles
-
Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street
12/18/2023
While the candidate was effective in Phase III results, Point’s stock price fell following the announcement. -
The year may be coming to a close, but there's no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.
-
Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome
12/18/2023
Notable Labs, Ltd. and CicloMed, LLC announced initial safety and efficacy data of fosciclopirox and the performance of PPMP, Notable’s Predictive Precision Medicines Platform, from the Phase 2a trial in adult patients with relapsed/refractory acute myeloid leukemia, R/R AML.
-
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
12/18/2023
Biora Therapeutics, Inc., the biotech company that is reimagining therapeutic delivery, announced an agreement with institutional investors Athyrium Capital Management, Davidson Kempner Capital Management, and Highbridge Capital Management to reduce the company’s net debt by 60% through a convertible note exchange which also brings $16.7 million in new capital.
-
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
12/18/2023
Jeff Wolf, CEO of NightHawk, commented, “We are generating strong interest in our CDMO services, given our state-of-the-art facility and the industry-wide lack of available capacity for large molecule manufacturing.
-
Grant of Options to Directors and Officers
12/18/2023
Arch Biopartners Inc., announced that its Board of Directors has granted a total of 350,000 stock options to directors and officers pursuant to the Company's stock option plan and the requirements of the TSX Venture Exchange.
-
Bone Biologics Announces 1-for-8 Reverse Stock Split
12/18/2023
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8.
-
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
12/18/2023
Propanc Biopharma, Inc. announced that a boutique advisory firm has been engaged to identify strategic investment opportunities primarily to fund the advancement of the Company’s lead product candidate, PRP, to the completion of the Company’s planned Phase I, First-In-Human study in advanced cancer patients suffering from solid tumors.
-
iCAD Expands Executive Sales Leadership Team as Business Grows
12/18/2023
iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, announced the expansion of its sales leadership with the addition of Peter Graham, as Senior Vice President, North American Sales and a role change for Bill Keyes to Senior Vice President, Global Sales Operations, both effective immediately.
-
Waters Corporation Board of Directors Named 2024 Public Company Board of the Year by National Association of Corporate Directors New England Chapter
12/18/2023
Waters Corporation announced that its Board of Directors has been named 2024 "Public Company Board of the Year" by the National Association of Corporate Directors New England Chapter.
-
Bicara Therapeutics Appoints Lara Meisner as Chief Legal Officer
12/18/2023
Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, announced the appointment of Lara Meisner as chief legal officer.
-
Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens
12/18/2023
Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has entered into an exclusive, worldwide license agreement with the National Institutes of Health (NIH) for intellectual property related to a library of T-Cell Receptors (TCRs) directed against multiple cancer neoantigens.
-
First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company
12/18/2023
First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”) today announced that the company has signed a non-binding term sheet for a business combination with ImmunogenX, a clinical-stage biotherapeutics company developing Phase 3-ready latiglutenase, a potentially first-in-class, targeted, oral biotherapeutic for celiac disease.
-
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant
12/18/2023
Oncotelic Therapeutics, Inc, unveils a state-of-the-art GMP Manufacturing Plant, a significant stride in biopharmaceutical innovation, through its joint venture Sapu Biosciences LLC.
-
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
12/18/2023
On December 7, 2023, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation ("ODD") to NXL-004, an investigational AAV gene therapy product being developed by NeuExcell Therapeutics Inc. ("NeuExcell"), for the treatment of malignant glioma.
-
Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors
12/18/2023
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, announced the appointment of Dr. K. Peter Hirth to its Board of Directors.
-
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
12/18/2023
ZyVersa Therapeutics, Inc. announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in BIO Partnering @ JPM being held January 8-12, 2024 in San Francisco.
-
Spectrum Solutions Names Bill Phillips as New Chief Executive Officer
12/18/2023
Spectrum Solutions® and its owned corporations, Alimetrix, Inc., and Microarrays, Inc., announced the appointment of Bill Phillips as the company’s new chief executive officer, replacing Stephen J. Fanning, who successfully served as Spectrum’s CEO for over four years.
-
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
12/18/2023
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS).
-
Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications
12/18/2023
Anagenex and Nimbus Therapeutics announced they have initiated a research collaboration.